Trinity Biotech Files August 2024 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Aug 21, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, disclosure
TL;DR
Trinity Biotech filed its monthly 6-K report, standard procedure for foreign issuers.
AI Summary
Trinity Biotech plc filed a Form 6-K on August 21, 2024, to report its activities for the month of August 2024. This filing is a report of a foreign private issuer and is being incorporated by reference into their Registration Statement.
Why It Matters
This filing provides routine updates for investors on the company's activities as a foreign private issuer, which is a standard disclosure requirement.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial results or significant corporate events.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- August 2024 (date) — Reporting period
- 20240821 (date) — Filing date
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What period does this report cover?
This report covers the month of August 2024.
Is Trinity Biotech plc required to file annual reports under Form 20-F or 40-F?
Yes, Trinity Biotech plc indicates it files annual reports under cover of Form 20-F.
Where is Trinity Biotech plc's principal executive office located?
Trinity Biotech plc's principal executive office is located at IDA Business Park, Bray, County Wicklow, Ireland.
What is the purpose of incorporating this Form 6-K into a Registration Statement?
This Form 6-K is being incorporated by reference into their Registration Statement, which is a standard practice for ongoing disclosures.
Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-08-21 16:40:05
Filing Documents
- zk2431905.htm (6-K) — 15KB
- exhibit_99-1.htm (EX-99.1) — 12KB
- image1.jpg (GRAPHIC) — 90KB
- 0001178913-24-002726.txt ( ) — 152KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ John Gillard John Gillard Chief Executive Officer Date: August 21, 2024